• STUDIES
    Participation is open to worldwide institutions.
    Read More
  • MEETINGS
    Since 1998, an Annual Meeting of the IELSG investigators has been regularly held.
    Read More
  • NEWSLETTER
    The IELSG Newsletter informs about studies, meetings and other research activities.
    Read More
  • PUBLICATIONS
    The results are presented to major congresses and published into peer-reviewed journals.
    Read More

Fighting cancer through research. You can support us by making a donation, however large or small.

Support Us

LATEST NEWS

  • Newsletter Number 53

    Click here to open pdf file

  • IELSG49
    IELSG49 Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL)
    Participants required: 24
    Investigator responsible(s): A. Stathis, D. Rossi, E. Zucca
    Objective(s): The primary objective of the IELSG49 trial is to determine the efficacy of tafasitamab in combination with acalabrutinib in patients with relapsed or refractory MZL.


ONGOING STUDIES

  • IELSG49
    IELSG49 Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL) Participants required: 24 […]
  • IELSG44
    IELSG44 FDG-PET evaluation for marginal zone lymphoma and its prognostic role: an international multicenter retrospective analysis (PIMENTO) Participants required: 350 Investigator responsible(s): […]
  • IELSG47 Study
    MALIBU trial – Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas

LATEST NEWSLETTER

PUBLICATIONS

Top